Steroidogenesis: Unanswered Questions

Trends in Endocrinology and Metabolism

Volumn 28, Issue 11, 2017, Pages 771-793

  Miller, Walter L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adrenal; adrenarche; androgens; cytochrome P450; StAR protein; steroids

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOCHROME P450 REDUCTASE; STEROID 17ALPHA MONOOXYGENASE; STEROIDOGENIC ACUTE REGULATORY PROTEIN; CHOLESTEROL; PHOSPHOPROTEIN; SEX HORMONE; STEROID;

ADRENARCHE; ANDROGEN SYNTHESIS; CONGENITAL ADRENAL HYPERPLASIA; GENE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPRODUCTION; REVIEW; RISK FACTOR; STEROIDOGENESIS; ANIMAL; BIOSYNTHESIS; LIPOGENESIS; METABOLISM; PHYSIOLOGY;

ANIMALS; CHOLESTEROL; GONADAL STEROID HORMONES; HUMANS; LIPOGENESIS; METABOLIC NETWORKS AND PATHWAYS; PHOSPHOPROTEINS; STEROIDS;

EID: 85030873550     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2017.09.002     Document Type: Review

References (109)

1. Miller, W.L., Auchus, R.J., The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr. Rev. 32 (2011), 81–151.
2. Miller, W.L., Bose, H., Early steps in steroidogenesis: intracellular cholesterol trafficking. J. Lipid Res. 52 (2011), 2111–2135.
3. Miller, W.L., Disorders in the initial steps of steroid hormone synthesis. J. Steroid Biochem. Mol. Biol. 165 (2017), 18–37.
4. Stocco, D.M., Clark, B.J., Regulation of the acute production of steroids in steroidogenic cells. Endocr. Rev. 17 (1996), 221–244.
5. Morohaku, K., et al. Translocator protein/peripheral benzodiazepine receptor is not required for steroid hormone biosynthesis. Endocrinology 155 (2014), 89–97.
6. Tu, L.N., et al. Peripheral benzodiazepine receptor/translocator protein global knock-out mice are viable with no effects on steroid hormone biosynthesis. J. Biol. Chem. 289 (2014), 27444–27454.
7. Banati, R., et al. Positron emission tomography and functional characterization of a complete PBR/TSPO knockout. Nat. Commun., 5, 2014, 5452.
8. Stocco, D.M., et al. A brief history of the search for the protein(s) involved in the acute regulation of steroidogenesis. Mol. Cell. Endocrinol. 441 (2017), 7–16.
9. Prasad, M., et al. Mitochondria-associated endoplasmic reticulum membrane (MAM) regulates steroidogenic activity via steroidogenic acute regulatory protein (StAR)–voltage-dependent anion channel 2 (VDAC2) interaction. J. Biol. Chem. 290 (2015), 2604–2616.
10. Prasad, M., et al. Mitochondrial metabolic regulation by GRP78. Sci. Adv., 3, 2017, e1602038.
11. Iaea, D.B., et al. Role of STARD4 in sterol transport between the endocytic recycling compartment and the plasma membrane. Mol. Biol. Cell 28 (2017), 1111–1122.
12. Miller, W.L., Tee, M.K., The post-translational regulation of 17,20 lyase. Mol. Cell. Endocrinol. 408 (2015), 99–106.
13. Peng, H.M., et al. Cytochrome b5 activates the 17,20-lyase activity of human cytochrome P450 17A1 by increasing the coupling of NADPH consumption to androgen production. Biochemistry, 55, 2016 4356–4365.
14. Pandey, A.V., et al. Protein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17. J. Biol. Chem. 278 (2003), 2837–2844.
15. Holien, J.K., et al. A homodimer model can resolve the conundrum as to how cytochrome P450 oxidoreductase and cytochrome b5 compete for the same binding site on cytochrome P450c17. Curr. Protein Pept. Sci. 18 (2017), 517–519.
16. Pandey, A.V., Miller, W.L., Regulation of 17,20 lyase activity by cytochrome b5 and by serine phosphorylation of P450c17. J. Biol. Chem. 280 (2005), 13265–13271.
17. Tee, M.K., Miller, W.L., Phosphorylation of human cytochrome P450c17 by p38α selectively increases 17,20 lyase activity and androgen synthesis. J. Biol. Chem. 288 (2013), 23903–23913.
18. Bremer, A.A., Miller, W.L., The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil. Steril. 89 (2008), 1039–1048.
19. Sondhi, V., et al. Impaired 17,20-lyase activity in male mice lacking cytochrome b5 in Leydig cells. Mol. Endocrinol. 30 (2016), 469–478.
20. Paris, D.B.B.P., et al. Birth of pouch young after artificial insemination in the Tammar wallaby (Macropus eugenii). Biol. Reprod. 72 (2005), 451–459.
21. Auchus, R.J., The backdoor pathway to dihydrotestosterone. Trends Endocrinol. Metab. 15 (2004), 432–438.
22. Kamrath, C., et al. Increased activation of the alternative ‘backdoor’ pathway in patients with 21-hydroxylase deficiency: evidence from urinary steroid hormone analysis. J. Clin. Endocrinol. Metab. 93 (2012), E367–E375.
23. Flück, C.E., et al. Why boys will be boys. Two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. Am. J. Hum. Genet. 89 (2011), 201–218.
24. Biason-Lauber, A., et al. Of marsupials and men: ‘backdoor’ dihydrotestosterone synthesis in male sexual differentiation. Mol. Cell. Endocrinol. 371 (2013), 124–132.
25. Dhayat, N.A., et al. Androgen biosynthesis during minipuberty favors the backdoor pathway over the classic pathway: insights into enzyme activities and steroid fluxes in healthy infants during the first year of life from the urinary steroid metabolome. J. Steroid Biochem. Mol. Biol. 165 (2017), 312–322.
26. Marti, N., et al. Genes and proteins of the alternative steroid backdoor pathway for dihydrotestosterone synthesis are expressed in the human ovary and seem enhanced in the polycystic ovary syndrome. Mol. Cell. Endocrinol. 441 (2017), 116–123.
27. Rege, J., et al. Liquid chromatography–tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation. J. Clin. Endocrinol. Metab. 98 (2013), 1182–1188.
28. Storbeck, K.H., et al. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?. Mol. Cell. Endocrinol., 377, 2013, 135.
29. Swart, A.C., et al. 11β-Hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione. J. Steroid Biochem. Mol. Biol. 138 (2013), 132–142.
30. Swart, A.C., Storbeck, K.H., 11β-hydroxyandrostenedione: downstream metabolism by 11βHSD, 17βHSD, and SRD5A produces novel substrates in familiar pathways. Mol. Cell. Endocrinol. 408 (2015), 114–123.
31. Turcu, A.F., et al. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. Eur. J. Endocrinol. 174 (2016), 601–609.
32. Imamichi, Y., et al. 11-Ketotestosterone is a major androgen produced in human gonads. J. Clin. Endocrinol. Metab. 101 (2016), 3582–3591.
33. Pretorius, E., et al. 11-Ketotestosterone and 11-ketodihydrotestosterone in castration resistant prostate cancer: potent androgens which can no longer be ignored. PLoS One, 11, 2016, e0159867.
34. du Toit, T., et al. Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC2-MS/MS quantification of 11β-hydroxytestosterone, 11keto-testosterone and 11keto-dihydrotestosterone. J. Steroid Biochem. Mol. Biol. 166 (2017), 54–67.
35. Turcu, A.F., Auchus, R.J., Clinical significance of 11-oxygenated androgens. Curr Opin Endocrinol Diabetes Obes 24 (2017), 252–259.
36. Yazawa, T., et al. Cyp11b1 is induced in the murine gonad by luteinizing hormone/human chorionic gonadotropin and involved in the production of 11-ketotestosterone, a major fish androgen: conservation and evolution of the androgen metabolic pathway. Endocrinology 149 (2008), 1786–1792.
37. Campana, C., et al. Development of a novel cell based androgen screening model. J. Steroid Biochem. Mol. Biol. 156 (2016), 17–22 201.
38. Turcu, A.F., et al. 11-Oxygenated androgens are biomarkers of adrenal volume and testicular addrenal rest tumors in 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 102 (2017), 2701–2710.
39. Krone, N., et al. Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). J. Steroid Biochem. Mol. Biol. 121 (2010), 496–504.
40. Wooding, K.M., Auchus, R.J., Mass spectrometry theory and application to adrenal diseases. Mol. Cell. Endocrinol. 371 (2013), 201–207.
41. Auchus, R.J., Steroid assays and endocrinology: best practices for basic scientists. Endocrinology 155 (2014), 2049–2051.
42. Mesiano, S., Jaffe, R.B., Developmental and functional biology of the primate fetal adrenal cortex. Endocr. Rev. 18 (1997), 378–403.
43. Goto, M., et al. In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development. J. Clin. Invest. 116 (2006), 953–960.
44. Asby, D.J., et al. The adrenal cortex and sexual differentiation during early human development. Rev. Endocr. Metab. Disord. 10 (2009), 43–49.
45. McMahon, S.K., et al. Neonatal complete generalized glucocorticoid resistance and growth hormone deficiency caused by a novel homozygous mutation in helix 12 of the ligand binding domain of the glucocorticoid receptor gene (NR3C1). J. Clin. Endocrinol. Metab. 95 (2010), 297–302.
46. Ben-David, S., et al. Parturition itself is the basis for fetal adrenal involution. J. Clin. Endocrinol. Metab. 92 (2007), 93–97.
47. Agrawal, V., et al. Potential role of increased oxygen tension in perinatal patterns of adrenal steroidogenesis. Pediatr. Res. 77 (2015), 298–309.
48. Abbott, D.H., Bird, I.M., Nonhuman primates as models for human adrenal androgen production: function and dysfunction. Rev. Endocr. Metab. Disord. 10 (2009), 33–42.
49. Bernstein, R.M., et al. Adrenal androgen production in catarrhine primates and the evolution of adrenarche. Am. J. Phys. Anthropol. 147 (2012), 389–400.
50. Maninger, N., et al. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front. Neuroendocrinol. 30 (2009), 65–91.
51. Ibáñez, L., et al. Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism. Rev. Endocr. Metab. Disord. 10 (2009), 63–76.
52. Nakamura, Y., et al. Adrenal changes associated with adrenarche. Rev. Endocr. Metab. Disord. 10 (2009), 19–26.
53. Hui, X.G., et al. Development of the human adrenal zona reticularis: morphometric and immunohistochemical studies from birth to adolescence. J. Endocrinol. 203 (2009), 241–252.
54. Huang, N., et al. Regulation of cytochrome b5 gene expression by Sp3, GATA-6, and NF-1 in human adrenal NCI-H295A cells. Mol. Endocrinol. 19 (2005), 2020–2034.
55. Missaghian, E., et al. Role of DNA methylation in the tissue-specific expression of the CYP17A1 gene for steroidogenesis in rodents. J. Endocrinol. 202 (2009), 99–109.
56. Pandey, A.V., Flück, C.E., NADPH P450 oxidoreductase: structure, function, and pathology of diseases. Pharmacol. Ther. 138 (2013), 229–254.
57. Nebert, D.W., et al. Human cytochromes P450 in health and disease. Philos. Trans. R. Soc. B, 368, 2013, 20120431.
58. Zanger, U.M., Schwab, M., Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138 (2013), 103–141.
59. Miller, W.L., Regulation of steroidogenesis by electron transfer. Endocrinology 146 (2005), 2544–2550.
60. Flück, C.E., et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley–Bixler syndrome. Nat. Genet. 36 (2004), 228–230.
61. Huang, N., et al. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutants. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 1733–1738.
62. Miller, W.L., et al. Consequences of POR mutations and polymorphisms. Mol. Cell. Endocrinol. 336 (2011), 174–179.
63. Pandey, A.V., et al. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol. Endocrinol. 21 (2007), 2579–2595.
64. Dhir, V., et al. Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol. Endocrinol. 21 (2007), 1958–1968.
65. Lv, J., et al. Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Pharmacogenet. Genomics 26 (2016), 80–87.
66. Elens, L., et al. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenet. Genomics 23 (2013), 148–155.
67. Tan, S.L., et al. Cytochrome P450 oxidoreductase genetic polymorphisms A503 V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement. Eur. J. Clin. Pharmacol. 69 (2013), 1769–1775.
68. Gomes, L.G., et al. The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 93 (2008), 2913–2916.
69. Xiao, X., et al. Functional POR A503V is associated with the risk of bladder cancer in a Chinese population. Sci. Rep., 5, 2015, 11751.
70. Li, H., et al. Associations of cytochrome P450 oxidoreductase genetic polymorphisms with smoking cessation in a Chinese population. Hum. Genet. 135 (2016), 1389–1397.
71. Frank, D., et al. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur. J. Clin. Pharmacol. 63 (2007), 321–333.
72. Liu, Y.T., et al. Drugs as CYP3A probes, inducers and inhibitors. Drug Metab. Rev. 39 (2007), 699–721.
73. Agrawal, V., et al. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase (POR). Pharmacogenet. Genomics 20 (2010), 611–618.
74. Tomalik-Scharte, D., et al. Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur. J. Endocrinol. 163 (2010), 919–924.
75. Zhang, X., et al. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab. Dispos. 39 (2011), 1433–1439.
76. Tee, M.K., et al. Transcriptional regulation of the human P450 oxidoreductase gene: hormonal regulation and influence of promoter polymorphisms. Mol. Endocrinol. 25 (2011), 715–731.
77. Compagnone, N.A., Mellon, S.H., Neurosteroids: biosynthesis and function of these novel neuromodulators. Front. Neuroendocrinol. 21 (2000), 1–58.
78. Slominski, A.T., et al. The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions. J. Steroid Biochem. Mol. Biol. 144 (2014), 28–39.
79. Slominski, A.T., et al. On the role of skin in the regulation of local and systemic steroidogenic activities. Steroids 103 (2015), 72–88.
80. Nikolakis, G., et al. Skin steroidogenesis in health and disease. Rev. Endocr. Metab. Disord. 17 (2016), 247–258.
81. Gomes, L.G., et al. Extra-adrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 94 (2009), 89–95.
82. Mellon, S.H., Neurosteroid regulation of central nervous system development. Pharmacol. Ther. 116 (2007), 107–124.
83. A receptors in the acute and chronic effects of ethanol: a decade of progress. Psychopharmacology 205 (2009), 529–564.
84. Porcu, P., et al. Neurosteroidogenesis today: novel targets for neuroactive steroid synthesis and action and their relevance for translational research. J. Neuroendocrinol., 28, 2016, 12351.
85. Therrell, B.L. Jr, et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 101 (1998), 583–590.
86. Gidlöf, S., et al. Nationwide neonatal screening for congenital adrenal hyperplasia in Sweden. JAMA Pediatr. 168 (2014), 567–574.
87. Tsuji, A., et al. Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study. BMC Pediatr., 15, 2015, 209.
88. Silveira, E.L., et al. Molecular analysis of CYP21A2 can optimize the follow-up of positive results in newborn screening for congenital adrenal hyperplasia. Clin. Genet. 76 (2009), 503–510.
89. Coeli-Lacchini, F.B., et al. A rational, non-radioactive strategy for the molecular diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Gene 526 (2013), 239–245.
90. Nascimento, M.L., et al. Ten-year evaluation of a Neonatal Screening Program for congenital adrenal hyperplasia. Arq. Bras. Endocrinol. Metabol. 58 (2014), 765–771.
91. de Carvalho, D.F., et al. Molecular CYP21A2 diagnosis in 480 Brazilian patients with congenital adrenal hyperplasia before newborn screening introduction. Eur. J. Endocrinol. 175 (2016), 107–116.
92. Therrell, B.L., et al. Current status of newborn screening worldwide: 2015. Semin. Perinatol. 39 (2015), 171–187.
93. Bryc, K., et al. The genetic ancestry of African Americans, Latinos, and European Americans across the United States. Am. J. Hum. Genet. 96 (2015), 37–53.
94. Tishkoff, S.A., et al. The genetic structure and history of Africans and African Americans. Science 324 (2009), 1035–1044.
95. 1000 Genomes Project Consortium, An integrated map of genetic variation from 1,092 human genomes. Nature 491 (2012), 56–65.
96. Cherradi, N., et al. Submitochondrial distribution of three key steroidogenic proteins (steroidogenic acute regulatory protein and cytochrome P450scc and 3β-hydroxysteroid dehydrogenase isomerase enzymes) upon stimulation by intracellular calcium in adrenal glomerulosa cells. J. Biol. Chem. 272 (1997), 7899–7907.
97. Rajapaksha, M., et al. An outer mitochondrial translocase, Tom22, is crucial for inner mitochondrial steroidogenic regulation in adrenal and gonadal tissues. Mol. Cell. Biol. 36 (2016), 1032–1047.
98. Storbeck, K.H., et al. Cytochrome b5 modulates multiple reactions in steroidogenesis bydiverse mechanisms. J. Steroid Biochem. Mol. Biol. 151 (2013), 66–73.
99. Lutfallah, C., et al. Newly proposed hormonal criteria via genotypic proof for type II 3β-hydroxysteroid dehydrogenase deficiency. J. Clin. Endocrinol. Metab. 87 (2002), 2611–2622.
100. Shi, Y., et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat. Genet. 44 (2012), 1020–1025.
101. Louwers, Y.V., et al. Cross-ethnic meta-analysis of genetic variants for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 98 (2013), E2006–2012.
102. Miller, W.L., Why nobody has P450scc (20,22 desmolase) deficiency. J. Clin. Endocrinol. Metab. 83 (1998), 1399–1400.
103. Griffin, A., et al. Ferredoxin 1b (Fdx1b) is the essential mitochondrial redox partner for cortisol biosynthesis in zebrafish. Endocrinology 157 (2016), 1122–1134.
104. Bair, S.R., Mellon, S.H., Deletion of the mouse P450c17 gene causes embryonic lethality. Mol. Cell. Biol. 24 (2004), 5383–5390.
105. Selvaraj, V., et al. Crucial role reported for TSPO in viability and steroidogenesis is a misconception. Commentary: conditional steroidogenic cell-targeted deletionof TSPO unveils a crucial role in viability and hormone-dependent steroid formation. Front. Endocrinol., 7, 2016, 91.
106. Wang, H., et al. Global deletion of TSPO does not affect the viability and gene expression profile. PLoS One, 11, 2016, e0167307.
107. Miller, W.L., The syndrome of 17,20 lyase deficiency. J. Clin. Endocrinol. Metab. 97 (2012), 59–67.
108. Gupta, M.K., et al. 5α-Reduced C21 steroids are substrates for human cytochrome P450c17. Arch. Biochem. Biophys. 418 (2003), 151–160.
109. Endo, T., et al. Truncated form of tenascin-X, XB-S, interacts with mitotic motor kinesin Eg5. Mol. Cell. Biochem. 320 (2009), 53–66.